EUCTR2005-004505-29-GB进行中（未招募）不适用
Phase II clinical trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with previously untreated unresectable liver-only metastases from colorectal cancer - BOXER
Royal Marsden NHS Trust0 个研究点目标入组 46 人开始时间: 2005年11月24日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 46
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologically proven diagnosis of colorectal adenocarcinoma
- •Metastatic disease present in the liver only.
- •Absence of extrahepatic metastases excluded by CT chest, abdomen and pelvis. Indeterminate CT findings may require verification by FDG-PET scanning.
- •Liver-only metastases determined to be unresectable at presentation on a pre-treatment liver MRI with an appropriate liver specific contrast (eg. TESLA) by a specialist multidisciplinary team (consisting of medical oncologist, hepatic surgeon and radiologist). Guidelines for determining unresectability include:presence of >4 metastases;size >5cm;location and distribution of metastatic disease within the liver unsuitable for resection with clear margins (eg. Involvement of both lobes of liver; invasion of intrahepatic vascular structures);extent of liver involvement precluding resection with adequate post-resection residual liver parenchyma volume for viable liver function in the immediate post-operative period;inability to retain adequate vascular in flow and out flow to maintain viable liver function; any liver-only metastases diagnosed synchronously with the primary tumour.
- •No previous treatment for metastatic colorectal cancer, including chemotherapy, targeted or experimental therapies (e.g. anti-VEGF or anti-EGFR), radiotherapy to the liver, or surgery or radiofrequency ablation to liver metastases.
- •If the primary colorectal tumour is in situ, the primary tumour must also be resectable with curative intent
- •Patients presenting with liver metastases only relapse after initially curative resection of their primary colorectal cancer followed by treatment with adjuvant chemotherapy may not be entered into the study if the relapse has occurred within 12 months of completion of adjuvant treatment
- •Adequate medical fitness to undergo neoadjuvant treatment and surgery with curative intent (hepatectomy +/- resection of primary tumour, if required)
- •Absence of pre-existing liver dysfunction of Childs Pugh Grade B or greater. Patients who are suspected of having pre-existing liver dysfunction due to clinical, biochemical or radiological findings, should have significant liver disease excluded by a liver biopsy prior to study entry.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •No major surgery, major trauma or open biopsy within 28 days prior to study entry. Patients requiring insertion of central venous access for treatment (e.g. due to poor venous access) should have the procedure performed at least 2 days before starting treatment
- •No serious, non-healing wound, ulcer, or bone fracture
- •Absence of obvious risk of requiring emergency surgery after commencement of study treatment, such as impending bowel obstruction
- •Absence of clinically significant (i.e. active) cardiovascular disease e.g. cerebrovascular accidents ( = 6 months prior to randomisation), myocardial infarction (= 1 year prior to randomisation), uncontrolled hypertension while receiving chronic medication, unstable angina, New York Heart Association (NYHA) Grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication
- •No recent history of any active gastrointestinal inflammatory condition such as peptic ulcer disease, diverticulitis or inflammatory bowel disease. If patients have a known diagnosis of any of the above, evidence of disease control is required by negative endoscopy within the past 28 days
- •No evidence of bleeding diathesis or coagulopathy
- •No recent commencement of full dose oral anticoagulation (warfarin), unless stable and within therapeutic range for at least 10 days. INR must be monitored closely after commencement of treatment due to potential for interaction between warfarin and capecitabine
- •No thrombolytic therapy within 10 days prior to commencement of study treatment
- •No chronic, daily treatment with high-dose aspirin (> 325mg/day) or nonsteroidal anti-inflammatory medications (those known to inhibit platelet function at doses used to treat chronic inflammatory diseases)
- •No chronic treatment with corticosteroids (dose of = 10 mg/day methylprednisolone equivalent) (excluding inhaled steroids)
- •No known allergy to Chinese hamster ovary cell proteins or other recombinant human or humanized antibodies or to any excipients of bevacizumab formulation, platinum compounds or to any other components of the study drugs
- •No proteinuria at baseline as defined by >1g of protein/24 hr by a 24-hour urine collection
- •No known peripheral neuropathy = CTCAE v 3.0 Grade 1 (absence of deep tendon reflexes (DTRs) as the sole neurological abnormality does not render the patient ineligible)
- •No known dihydropyrimidine dehydrogenase (DPD) deficiency
- •Absence of contraindications to MRI (eg. patients with pacemakers)
- •WHO performance status 0-2
- •Adequate bone marrow function with platelets > 100 x 109/l; WBC > 3 x 109/l; neutrophils > 1.5 x 109/l
- •Serum bilirubin < 1.5 × upper limit of institutional normal range (ULN) and transaminases < 2.5? ULN (see exclusion criteria for hepatic dysfunction)
- •Serum creatinine less than ULN or calculated creatinine clearance >50ml/min (Cockcroft and Gault formula).
- •Absence of lack of physical integrity of the upper gastro-intestinal tract, malabsorption syndrome, or inability to take oral medication
- •In females of childbearing potential, pregnancy must be excluded, either with a negative pregnancy test within 7 days prior of commencing treatment or history of amenorrhea greater than 2 years. Fertile women (< 2 years after last menstruation) and men of childbearing potential not willing to use effective means of contraception may not enter the study
- •No other malignancies within the last 5 years (other than curatively treated basal cell carcinoma of the skin and/or in
研究者
相似试验
已完成
2 期
P II study of CapeOX therapy for small intestinal cancerunresectable or recurrent small bowel adenocarcinoma with no prior treatmentJPRN-jRCTs041180011Yasui Hirofumi17
招募中
2 期
A phase II trial of oxaliplatin, capecitabine, irinotecan (XELOXIRI) and bevacizumab as first-line therapy for patients with metastatic colorectal cancermetastatic colorectal cancerJPRN-UMIN000039783Sapporo Medical University School of Medicine47
进行中（未招募）
不适用
Prospective phase II trial using Capecitabine and Trastuzumab for therapy of female patients with cerebral metastasizing, HER2-overexpressing breast cancer - HERXECNS-metastasizing HER2-overexpressing breast cancerMedDRA version: 9.1Level: PTClassification code 10057654Term: Breast cancer femaleMedDRA version: 9.1Level: PTClassification code 10006202Term: Breast cancer stage IVEUCTR2007-003634-42-DEKlinikum der Universität München, Standort Großhadern
已完成
不适用
Phase II study of Capecitabine + oxaliplatin(CapeOx) for elderly patients with untreated metastatic gastric cancer <TCOG GI-1601>ntreated metastatic gastric cancerJPRN-UMIN000022450The Tokyo Cooperative Oncology Group110
已完成
不适用
Phase I trial of capecitabine, oxaliplatin and irinotecan combination chemotherapy (XELOXIRI) for advanced gastric cancerAdvanced gastric cancerJPRN-UMIN000022861Kyushu University18